Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease

2010 ◽  
Vol 48 (03) ◽  
pp. 206-213 ◽  
Author(s):  
M. Abe ◽  
K. Okada ◽  
T. Maruyama ◽  
S. Matsumoto ◽  
K. Matsumoto
Keyword(s):  
Low Dose ◽  
Angiotensin Receptor Blockers ◽  
High Dose ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering ◽  
Hypertensive Patients ◽  
Normal Dose ◽  
Antiproteinuric Effect ◽  
Pressure Lowering ◽  
Receptor Blockers

scholarly journals ROADMAP and ORIENTAL Trials: The Re-emergence of J-Curve Ghost?

2011 ◽  
Vol 2 ◽  
pp. JCM.S7521 ◽  
Author(s):  
Yoshiyuki Hamamoto ◽  
Hiroyuki Koshiyama
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Events ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering ◽  
J Curve ◽  
Pressure Lowering ◽  
Risk Patients ◽  
Receptor Blockers

It still remains unknown whether angiotensin-receptor blockers (ARBs) are cardioprotective in patients with type 2 diabetes. The recent two clinical trials, the ROADMAP and the ORIENT, have suggested that fatal cardiovascular events or cardiovascular deaths were unexpectedly higher in olmesartan group. These results suggest that aggressive blood pressure lowering may cause a higher risk in some high-risk patients, especially in those with preexisting coronary heart disease, indicating a possibility that the J-curve phenomenon may exist in some group of patients.

scholarly journals Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering

2005 ◽  
Vol 16 (12) ◽  
pp. 3631-3641 ◽  
Author(s):  
Yuko Izuhara ◽  
Masaomi Nangaku ◽  
Reiko Inagi ◽  
Naoto Tominaga ◽  
Toru Aizawa ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering ◽  
Pressure Lowering ◽  
Receptor Blockers
Sign in / Sign up

Export Citation Format

Share Document